연구동향 분석

Tumor microenvironment (TME) remodeling and response to anticancer treatment in advanced gastric cancer = 위암 내 항암 치료에 대한 종양미세환경 개조와 반응성

안민애 2022년

논문상세정보
인용/피인용
' Tumor microenvironment (TME) remodeling and response to anticancer treatment in advanced gastric cancer = 위암 내 항암 치료에 대한 종양미세환경 개조와 반응성' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Gastric cancer
  • Next Generation Sequencing
  • Single cell sequencing
  • Tumor microenvironment
  • chemotherapy
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
607 0

0.0%

' Tumor microenvironment (TME) remodeling and response to anticancer treatment in advanced gastric cancer = 위암 내 항암 치료에 대한 종양미세환경 개조와 반응성' 의 참고문헌

  • Weichhart T. Metabolic Programming of Macrophages : Implications in the Pathogenesis of Granulomatous Disease
    Wilson JL , Mayr HK 10:2265 doi 10.3389/fimmu.2019.02265 . [2019]
  • FACETS : allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing
    Shen R , Seshan VE . 44 ( 16 ) : e131 doi 10.1093/nar/gkw520 . [2016]
  • Durbin R. Fast and accurate short read alignment with Burrows- Wheeler transform
    Li H , 25 ( 14 ) :1754-60 doi 10.1093/bioinformatics/btp324 . [2009]
  • 9. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021;398(10294):27-40 doi 10.1016/S0140- 6736(21)00797-2.
  • 8. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018;4(5):e180013 doi 10.1001/jamaoncol.2018.0013.
    [2018]
  • 72. Goltsev Y, Samusik N, Kennedy-Darling J, Bhate S, Hale M, Vazquez G, et al. Deep Profiling of Mouse Splenic Architecture with CODEX Multiplexed Imaging. Cell 2018;174(4):968-81 e15 doi 10.1016/j.cell.2018.07.010.
    [2018]
  • 71. Schurch CM, Bhate SS, Barlow GL, Phillips DJ, Noti L, Zlobec I, et al. Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. Cell 2020;182(5):1341-59 e19 doi 10.1016/j.cell.2020.07.005.
    [2020]
  • 70. Wolock SL, Lopez R, Klein AM. Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic Data. Cell Syst 2019;8(4):281-91 e9 doi 10.1016/j.cels.2018.11.005.
    [2019]
  • 7. Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol 2019;30(2):250-8 doi 10.1093/annonc/mdy540.
  • 69. Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, 3rd, et al. Comprehensive Integration of Single-Cell Data. Cell 2019;177(7):1888-902 e21 doi 10.1016/j.cell.2019.05.031.
    [2019]
  • 68. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 2011;12:323 doi 10.1186/1471-2105-12-323.
    [2011]
  • 67. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner.Bioinformatics 2013;29(1):15-21 doi 10.1093/bioinformatics/bts635.
    [2013]
  • 66. Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol 2016;17:31 doi 10.1186/s13059-016-0893-4.
    [2016]
  • 64. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The Ensembl Variant Effect Predictor. Genome Biol 2016;17(1):122 doi 10.1186/s13059-016-0974-4.
    [2016]
  • 63. International HapMap C, Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, et al. Integrating common and rare genetic variation in diverse human populations. Nature 2010;467(7311):52-8 doi 10.1038/nature09298.
    [2010]
  • 62. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature 2015;526(7571):68-74 doi 10.1038/nature15393.
    [2015]
  • 61. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001;29(1):308-11 doi 10.1093/nar/29.1.308.
    [2001]
  • 60. Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, Kallberg M, et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods 2018;15(8):591-4 doi 10.1038/s41592-018-0051-x.
    [2018]
  • 6. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15(11):1224-35 doi 10.1016/S1470-2045(14)70420- 6.
  • 59. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013;31(3):213-9 doi 10.1038/nbt.2514.
    [2013]
  • 58. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20(9):1297-303 doi 10.1101/gr.107524.110.
    [2010]
  • 56. S.J. Klempner1 CS, J. Chao3, V. Chiu4, D. Mahalingam5, H. Uronis6, M. Kagey7, J. Baum7, F. Dayyani8, J. Song9, J. Wang10, S. Iqbal11, M. Tejani12, M.B. Sonbol13, A.J. Scott14, Z.A. Wainberg15, J.A. Ajani16. DKN-01 in combination with tislelizumab and chemotherapy as a firstline therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial. Annals of Oncology 2021.
  • 55. Chen R, Smith EC, Chan SWS, Hueniken K, Brown MC, Majeed H, et al. Comparison of care patterns for hospitalized immune-related adverse events (irAEs) between melanoma patients on combination immune checkpoint inhibitor (ICI) therapy versus ICI monotherapy. Journal of Clinical Oncology 2019;37(8_suppl):85- doi 10.1200/JCO.2019.37.8_suppl.85.
    [2019]
  • 54. Zhang M, Hu S, Min M, Ni Y, Lu Z, Sun X, et al. Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing. Gut 2021;70(3):464-75 doi 10.1136/gutjnl-2019-320368.
  • 53. Wang R, Dang M, Harada K, Han G, Wang F, Pool Pizzi M, et al. Singlecell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med 2021;27(1):141-51 doi 10.1038/s41591-020-1125-8.
  • 52. Sathe A, Grimes SM, Lau BT, Chen J, Suarez C, Huang RJ, et al. Single- Cell Genomic Characterization Reveals the Cellular Reprogramming of the Gastric Tumor Microenvironment. Clin Cancer Res 2020;26(11):2640-53 doi 10.1158/1078-0432.CCR-19-3231.
    [2020]
  • 51. Lipson EJ, Tawbi HA-H, Schadendorf D, Ascierto PA, Matamala L, Gutiérrez EC, et al. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). Journal of Clinical Oncology 2021;39(15_suppl):9503- doi 10.1200/JCO.2021.39.15_suppl.9503.
  • 50. Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, et al. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clin Cancer Res 2019;25(15):4663-73 doi 10.1158/1078-0432.CCR-18-4142.
    [2019]
  • 5. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9(3):215-21 doi 10.1016/S1470-2045(08)70035-4.
    [2008]
  • 49. Hennequin A, Derangere V, Boidot R, Apetoh L, Vincent J, Orry D, et al. Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. Oncoimmunology 2016;5(2):e1054598 doi 10.1080/2162402X.2015.1054598.
    [2016]
  • 48. Fristedt R, Borg D, Hedner C, Berntsson J, Nodin B, Eberhard J, et al. Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. J Gastrointest Oncol 2016;7(6):848-59 doi 10.21037/jgo.2016.11.07.
    [2016]
  • 47. Candas-Green D, Xie B, Huang J, Fan M, Wang A, Menaa C, et al. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nat Commun 2020;11(1):4591 doi 10.1038/s41467-020-18245-7.
    [2020]
  • 46. Vitale I, Shema E, Loi S, Galluzzi L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med 2021;27(2):212- 24 doi 10.1038/s41591-021-01233-9.
  • 45. van de Haar J, Hoes LR, Roepman P, Lolkema MP, Verheul HMW, Gelderblom H, et al. Limited evolution of the actionable metastatic cancer genome under therapeutic pressure. Nat Med 2021;27(9):1553- 63 doi 10.1038/s41591-021-01448-w.
  • 44. Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, et al. Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discov 2018;8(1):49-58 doi 10.1158/2159-8290.CD-17-0787.
    [2018]
  • 43. Derks S, de Klerk LK, Xu X, Fleitas T, Liu KX, Liu Y, et al. Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. Ann Oncol 2020;31(8):1011-20 doi 10.1016/j.annonc.2020.04.011.
    [2020]
  • 42. Bejarano L, Jordao MJC, Joyce JA. Therapeutic Targeting of the Tumor Microenvironment. Cancer Discov 2021;11(4):933-59 doi 10.1158/2159- 8290.CD-20-1808.
  • 41. Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, et al. Developmental Relationships of Four Exhausted CD8(+) T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. Immunity 2020;52(5):825-41 e8 doi 10.1016/j.immuni.2020.04.014.
    [2020]
  • 40. Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an openlabel, single-arm, phase 2 trial. Lancet Oncol 2020;21(6):821-31 doi 10.1016/S1470-2045(20)30169-8.
    [2020]
  • 4. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358(1):36-46 doi 10.1056/NEJMoa073149.
    [2008]
  • 39. Steen CB, Liu CL, Alizadeh AA, Newman AM. Profiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx. Methods Mol Biol 2020;2117:135-57 doi 10.1007/978-1-0716-0301-7_7.
    [2020]
  • 38. Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol 2019;37(7):773-82 doi 10.1038/s41587-019-0114-2.
    [2019]
  • 37. Street K, Risso D, Fletcher RB, Das D, Ngai J, Yosef N, et al. Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genomics 2018;19(1):477 doi 10.1186/s12864-018-4772-0.
    [2018]
  • 35. Lee HO, Hong Y, Etlioglu HE, Cho YB, Pomella V, Van den Bosch B, et al. Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. Nat Genet 2020;52(6):594-603 doi 10.1038/s41588-020-0636-z.
    [2020]
  • 34. Chen Q, Han B, Meng X, Duan C, Yang C, Wu Z, et al. Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma. Int J Cancer 2019;145(2):517-30 doi 10.1002/ijc.32102.
    [2019]
  • 33. Vogl T, Eisenblatter M, Voller T, Zenker S, Hermann S, van Lent P, et al. Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity. Nat Commun 2014;5:4593 doi 10.1038/ncomms5593.
    [2014]
  • 32. Langlais D, Barreiro LB, Gros P. The macrophage IRF8/IRF1 regulome is required for protection against infections and is associated with chronic inflammation. J Exp Med 2016;213(4):585-603 doi 10.1084/jem.20151764.
    [2016]
  • 31. Jayasingam SD, Citartan M, Thang TH, Mat Zin AA, Ang KC, Ch'ng ES. Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human CancerTissue: Technicalities and Challenges in Routine Clinical Practice. Front Oncol 2019;9:1512 doi 10.3389/fonc.2019.01512.
    [2019]
  • 30. Wu S, Zhang Q, Zhang F, Meng F, Liu S, Zhou R, et al. HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. Nat Cell Biol 2019;21(8):1027-40 doi 10.1038/s41556-019-0352-z.
    [2019]
  • 3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97 doi 10.1016/S0140- 6736(10)61121-X.
  • 29. Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, et al. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J Clin Invest 2019;129(11):4850-62 doi 10.1172/JCI127471.
    [2019]
  • 28. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 2017;17(2):97- 111 doi 10.1038/nri.2016.107.
    [2017]
  • 27. Kwon M, An M, Klempner SJ, Lee H, Kim KM, Sa JK, et al. Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer. Cancer Discov 2021;11(9):2168-85 doi 10.1158/2159-8290.CD-21-0219.
  • 26. Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods 2019;16(12):1289-96 doi 10.1038/s41592-019-0619-0.
    [2019]
  • 25. Parsons MJ, Tammela T, Dow LE. WNT as a Driver and Dependency in Cancer. Cancer Discov 2021 doi 10.1158/2159-8290.CD-21-0190.
  • 24. Coates PJ, Rundle JK, Lorimore SA, Wright EG. Indirect macrophage responses to ionizing radiation: implications for genotype-dependent bystander signaling. Cancer Res 2008;68(2):450-6 doi 10.1158/0008- 5472.CAN-07-3050.
    [2008]
  • 23. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 2013;14:7 doi 10.1186/1471-2105-14-7.
    [2013]
  • 22. Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 2021;39(6):845-65.e7 doi 10.1016/j.ccell.2021.04.014.
  • 21. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature 2020;578(7793):94-101 doi 10.1038/s41586-020-1943-3.
    [2020]
  • 20. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513(7517):202- 9 doi 10.1038/nature13480.
    [2014]
  • 2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359-86 doi 10.1002/ijc.29210.
    [2015]
  • 19. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010;70(8):3052-61 doi 10.1158/0008- 5472.CAN-09-3690.
    [2010]
  • 18. Galetto A, Buttiglieri S, Forno S, Moro F, Mussa A, Matera L. Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs 2003;14(10):833-43 doi 10.1097/00001813-200311000-00010.
    [2003]
  • 17. Wang W, Wu L, Zhang J, Wu H, Han E, Guo Q. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model. Biochem Biophys Res Commun 2017;487(1):1-7 doi 10.1016/j.bbrc.2016.12.180.
    [2017]
  • 16. Tel J, Hato SV, Torensma R, Buschow SI, Figdor CG, Lesterhuis WJ, et al. The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. Cancer Immunol Immunother 2012;61(7):1101-11 doi 10.1007/s00262-011-1189-x.
    [2012]
  • 15. Park DS, Robertson-Tessi M, Luddy KA, Maini PK, Bonsall MB, Gatenby RA, et al. The Goldilocks Window of Personalized Chemotherapy: Getting the Immune Response Just Right. Cancer Res 2019;79(20):5302-15 doi 10.1158/0008-5472.CAN-18-3712.
    [2019]
  • 14. Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol 2019;30(2):219- 35 doi 10.1093/annonc/mdy551.
    [2019]
  • 13. Mansoor W, Kulkarni AS, Kato K, Sun J-M, Shah MA, Enzinger PC, et al. Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study. Journal of Clinical Oncology 2021;39(3_suppl):168- doi 10.1200/JCO.2021.39.3_suppl.168.
  • 12. Chung HC, Bang Y-J, Fuchs CS, Qin S, Satoh T, Shitara K, et al. KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study. Journal of Clinical Oncology 2020;38(4_suppl):TPS463-TPS doi 10.1200/JCO.2020.38.4_suppl.TPS463.
    [2020]
  • 11. Kato K, Shah MA, Enzinger P, Bennouna J, Shen L, Adenis A, et al. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol 2019;15(10):1057-66 doi 10.2217/fon-2018-0609.
    [2019]
  • 10. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet 2017;390(10111):2461- 71 doi 10.1016/S0140-6736(17)31827-5.
  • 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424 doi 10.3322/caac.21492.
    [2018]